Junshi Biosciences announced 2024 financial results with revenue of RMB1,948 million and decreased losses.

From GlobeNewswire: 2025-03-28 21:35:00

Shanghai Junshi Biosciences Co., Ltd announced its financial results for 2024, with total revenue of approximately RMB1,948 million and a decrease in loss attributable to owners by 44% compared to 2023. The company’s R&D expenses decreased by 34% due to cost control efforts. Junshi Biosciences also achieved milestones in drug development, including approvals for toripalimab in various countries for the treatment of different indications. The company aims to provide innovative therapies for cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences has a diversified R&D pipeline with over 50 drug candidates and a mission to provide affordable and innovative drugs globally.



Read more at GlobeNewswire: Junshi Biosciences Announces 2024 Full Year Financial